Dyskinesias and associated psychiatric disorders following streptococcal infections

R C Dale, I Heyman, R A H Surtees, A J Church, G Giovannoni, R Goodman, B G R Neville

Arch Dis Child 2004;89:604–610. doi: 10.1136/adc.2003.031856

Dyskinesias are purposeless and involuntary movements. They are classified according to the speed, rhythm, and suppressibility of the movements, and include chorea, dystonia (including athetosis), tremor, myoclonus, tics, and stereotypies. A broad spectrum of congenital and acquired brain disease (usually involving the basal ganglia) can result in dyskinetic movements.

The first description of a dyskinetic movement disorder was by Thomas Sydenham in the seventeenth century. He described a sudden onset dancing movement disorder in previously well children that was also termed “St Vitus dance”. However, it was not until the twentieth century that Sydenham’s chorea was confirmed to be a late manifestation of β haemolytic streptococcus (BHS) infection, thereby becoming one of the major criteria of rheumatic fever. Until the 1980s, chorea was considered the only extrapyramidal movement disorder occurring in the aftermath of BHS infection. However, the difficulty distinguishing chorea from tic disorders and myoclonus in the context of Sydenham’s chorea has been discussed throughout the twentieth century.

Recently, there has been a resurgence of interest in the spectrum of post-streptococcal movement disorders with the recognition of tic disorders and dystonia after streptococcal infections. The recognition that chorea, tics, and dystonia may occur as immune mediated complications of BHS infection suggests that the spectrum of post-streptococcal autoimmune basal ganglia disorders may be broader than previously described. These extrapyramidal movements are commonly associated with emotional and behavioural alteration, particularly disorders such as obsessive-compulsive disorder and anxiety, but also attention deficit-hyperactivity disorder (ADHD) and conduct disorders. Tic disorders and/or obsessive-compulsive disorder (OCD) associated with streptococcal infections have been given the acronym PANDAS (paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) by Swedo et al, who proposed that there must be two or more symptom exacerbations temporally related to streptococcal infections.

There is increasing evidence that both SC and PANDAS are mediated secondary to immune reactivity against the brain, specifically the basal ganglia. Support for this concept comes from early pathological studies of SC, which showed inflammatory changes predominantly of the basal ganglia and to a lesser extent the cortex. In addition, recent studies of both SC and PANDAS have shown selective enlargement of the basal ganglia using volumetric MR imaging. The proposed mechanism of post-streptococcal CNS disease is auto-antibody mediated neuronal dysfunction.

We report our experience of post-streptococcal dyskinetic extrapyramidal movements at the beginning of the twenty-first century. Participation in multidisciplinary clinics for children with movement disorders can be viewed as a natural progression of research that has defined the nature of these disorders.
first century. In addition, we aimed to define the accompanying psychiatric disorders that are often more impairing than the extra movements. These conditions represent a putative autoimmune model of acquired movement and psychiatric disorders, which may provide insight into the neuroanatomy and neurobiology of common neuropsychiatric syndromes.

METHODS

Patients

Patients were referred between 1999 and 2002 by their general practitioner or paediatrician for investigation and management of an acute onset or relapsing movement disorder. All patients included in this report had disease onset shortly after streptococcal pharyngeal infection, or suffered two or more relapses after streptococcal pharyngeal infections. Evidence of haemolytic streptococcal (BHS) infection was evident in all patients, and was diagnosed when a clinical episode of pharyngitis occurred with laboratory evidence of BHS infection (growth of BHS organism on pharyngeal swab, or increased acute streptococcal serology with reduction in serology 3–6 months later).

Movement disorders were initially diagnosed by RCD, and conform to accepted diagnostic definitions. Movement disorders were video-recorded and reviewed by two experienced child neurologists (BGRN and RAHS) in order to validate the movement disorder classifications, with discussion and agreement on problematic disorders. Investigations for an alternative cause of chorea, dystonia, and myoclonus (copper, caeruloplasmin, antinuclear antibody, thyroid function tests, lactate, plasma amino acids, and urine organic acids) were normal in all patients. MRI brain scanning was performed in 26 and was normal in 23. Three patients had localised inflammatory changes in the basal ganglia seen on T2 weighted imaging.

Presence of psychopathology was assessed using the Strengths and Difficulties Questionnaire (SDQ), and the Development and Well-Being Assessment (DAWBA) by RCD. The DAWBA is a diagnostic interview that combines structured and semi-structured features. These data were reviewed by an experienced child psychiatrist (IH), and ICD-10 psychiatric diagnoses were derived. Normative data using these measures have previously been obtained on a representative sample of 10 438 British 5–15 year olds. These normative data were used for comparison.

Table 1

<table>
<thead>
<tr>
<th>Age of movement disorder onset (y), sex</th>
<th>Movement disorder</th>
<th>ICD-10 psychiatric disorders</th>
<th>Movement disorder course (disease duration in years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2, M</td>
<td>Dystonia, chorea</td>
<td>–</td>
<td>Relapsing remitting (1.8)</td>
</tr>
<tr>
<td>1.3, F</td>
<td>Chorea</td>
<td>–</td>
<td>Persistent (1)</td>
</tr>
<tr>
<td>1.5, M</td>
<td>Chorea</td>
<td>–</td>
<td>Persistent (1.3)</td>
</tr>
<tr>
<td>2, M</td>
<td>Tics</td>
<td>OCD, social phobia, depression</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>2, F</td>
<td>Chorea, dystonia</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>2, M</td>
<td>Myoclonus, dystonia</td>
<td>Panic attacks, gen. anxiety</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>3, M</td>
<td>Tics</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>3, F</td>
<td>Stereotypies</td>
<td>OCD</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>4, M</td>
<td>Dystonia</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>4, F</td>
<td>Chorea</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>5, F</td>
<td>Tics</td>
<td>Sep. anxiety, gen. anxiety, OCD</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>5, F</td>
<td>Tics</td>
<td>Trichotillomania, depression</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>5, F</td>
<td>Tics</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>6, M</td>
<td>Tics</td>
<td>OCD</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>6, F</td>
<td>Tics</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>7, M</td>
<td>Tics</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>7, M</td>
<td>Tics</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>8, F</td>
<td>Tics</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>8, F</td>
<td>Tics</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
<tr>
<td>8, F</td>
<td>Dystonia, chorea</td>
<td>–</td>
<td>Persistent (13)</td>
</tr>
</tbody>
</table>

OCD, obsessive-compulsive disorder; OCC, oppositional defiant disorder.
defined as acute if less than one year duration, chronic if more than one year.

**Streptococcal serology**
Anti-streptolysin O titres and anti-DNase B titres were measured using the Dade Behring BN II nephelometer. All controls were within acceptable parameters. ASOT greater than 200 IU/ml and anti-DNase B greater than 300 IU/ml were considered significant according to WHO guidelines. Serology was repeated 3–6 months later to confirm reduction in titres. In order to establish the prevalence of positive streptococcal serology in a childhood population, controls with other neurological disease of metabolic, infectious, and other aetiologies (n = 100, mean age 7.5 years, median age 7 years, 50 males; see accompanying paper), were recruited steadily over the same time period from the same institution.

**Statistics**
Clinical differences between patient groups and controls or normative data were examined using the $\chi^2$ test or the Mann-Whitney test as appropriate. Anti-streptolysin-O and anti-DNase B titres in patients and controls were analysed using the non-parametric Mann-Whitney test.

**RESULTS**

**Patients**
Table 1 provides details of the patients with respect to movement and psychiatric disorders.

**Age and sex**
The age range of movement disorder onset was 1.2–16 years (mean 7.25 years, median 7 years); 21 patients were male, 19 female.

**Preceding medical history**
Psychiatric symptoms were present before movement disorder onset in seven patients (17.5%): attention deficit-hyperactivity disorder, n = 6 (one with co-morbid OCD and generalised anxiety); and post-traumatic stress disorder, n = 1. Other past medical history included cows’ milk protein allergy (n = 1), asthma (n = 1), and moyo-moya disease (n = 1).

**Precipitating infectious illness**
Thirty four patients (85%) had an infectious illness compatible with BHS shortly before movement disorder onset. The illnesses were described as sore throat/tonsillitis (n = 22), upper respiratory tract infection (n = 9), cervical lymphadenopathy (n = 2), and scarlet fever (n = 1). The remaining six patients did not have a clinical history of BHS infection at movement disorder onset, but subsequently had two or more relapses associated with streptococcal infections. BHS organisms were grown from pharyngeal cultures in six patients (five group A, one group G). Streptococcal serology provided evidence of BHS infection in all other patients. The mean ASOT values were statistically increased in the dyskinesia cohort (n = 40, median 453 IU/ml, mean 529 IU/ml, confidence intervals of mean 415–643) compared to the neurology controls (median 100 IU/ml, mean 151 IU/ml, confidence intervals of mean 102–200) ($p < 0.000$). Likewise, anti-DNase B was statistically increased in the dyskinesia cohort (median 373 IU/ml, mean 566 IU/ml, confidence intervals of mean 396–736) compared to the neurology control groups (median 196 IU/ml, mean 213 IU/ml, confidence intervals of mean 128–298 IU/ml) ($p < 0.000$) (figs 1 and 2). The mean latency between infection and movement disorder onset was 18.9 days (range 1–67 days).

**Movement disorder (table 1)**
The movement disorder onset was often abrupt, regardless of the dyskinesia phenotype. The most frequent dyskinesias were chorea (n = 20) and motor tics (n = 16). The first recorded motor tics were eye blinking/eye deviation (n = 4), head flicks (n = 3), assorted facial tics (n = 4), shoulder or upper limb tics (n = 3), and truncal tics (n = 2). Other dyskinesias were dystonia (n = 5), tremor (n = 3), stereotypies (n = 2), opsoclonus (n = 2), and myoclonus (n = 1). One patient with dystonia, and one patient with episodic (paroxysmal) dystonic choreoathetosis, have been previously
described. Seventeen patients had one or more vocal tics: 13 associated with motor tics, two with chorea, one with myoclonus, and one with stereotypes.

### Psychiatric disorders (tables 1 and 2)

Acute emotional and/or behavioural alteration occurred in 33 patients (82.5%). Most frequently reported acute changes were emotional lability (n = 13, 32.5%), anxiety (n = 11, 27.5%), obsessions and/or compulsions (n = 9, 22.5%), and depression (n = 7, 17.5%). Other common behavioural changes included aggressive, oppositional, or disruptive behaviours (n = 14, 35%) and attention deficit (n = 11, 17.5%).

Less common psychiatric manifestations included echolalia (n = 4), visual hallucinations (n = 2), and social disinterest (n = 2). Formal psychiatric assessments were carried out at least two weeks after the acute presentation. One or more ICD-10 diagnoses were made in 25 patients (62.5%). Thirteen patients (32.5%) had two or more psychiatric diagnoses. Table 2 presents the ICD-10 diagnoses, with comparison to previously derived normative data.

### Other neurological features

Hypotonia and bulbar dysfunction were common in the chorea subgroup (dysarthria occurred in half of the chorea patients). Sleep disorder occurred in nine patients (22.5%), particularly insomnia during the acute phases. Less common features included reduced consciousness (n = 2), epileptic seizures (n = 2), and mutism (n = 2).

### Systemic features

Systemic complications occurred in nine patients (22.3%), and affected the chorea patients only (47.5% of chorea patients had systemic features); five had carditis defined using echocardiography (four with mitral regurgitation). Two patients had arthritis, and three other patients had arthralgia. One further patient had a vasculitic rash, but no patients had erythema marginatum. Systemic complications always preceded the neurological syndrome.

### Family history

Sixteen patients (40%) had a family history of psychiatric or movement disorders in first degree family members. Ten patients (25%) had at least one family member with a history of movement disorders: motor tics in childhood (n = 7), Sydenham’s chorea (n = 2), and Tourette syndrome (n = 1). Family history of psychiatric disorders (ICD-10) was present in 11 patients (27.5%): obsessive-compulsive disorder (n = 5), depression (n = 4), hyperactivity (n = 3), anxiety, conduct disorder, and chronic fatigue syndrome (all n = 1) (some family members had more than one psychiatric diagnosis).

A family history of post-streptococcal autoimmune complications in first or second degree family members was present in eight patients (20%): Sydenham’s chorea (n = 3), PANDAS (n = 3), and rheumatic carditis (n = 2).

### Subsequent movement disorder outcome (table 1)

Patients with persistent disease are still under medical care. The mean duration of disease in this cohort is currently 2.7 years (2 months–13 years). Eleven (27.5%) patients have had a monophasic disorder with complete resolution. Of the 29 patients (72.5%) with continuing symptoms, 15 (37.5%) have persistent static disease and 14 (35%) have a relapsing remitting course associated with further infections. All of the tic patients fulfilled a diagnosis of PANDAS. Although there was evidence of streptococcal infections during the majority of exacerbations, two patients had relapses after apparent viral infections, and one patient had an exacerbation after a routine vaccination. Nine of the 16 patients with motor tics (56%) fulfilled a diagnosis of Tourette syndrome ICD-10.

### Table 2 Psychiatric diagnoses in post-streptococcal dyskinesia cohort (n = 40) and national comparison group (n = 10 438)

<table>
<thead>
<tr>
<th>ICD-10 diagnosis</th>
<th>Point prevalence</th>
<th>Normal data</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any ICD-10 diagnosis</td>
<td>62.5%</td>
<td>8.9%</td>
<td>0.000</td>
</tr>
<tr>
<td>Emotional disorder</td>
<td>47.5%</td>
<td>4.3%</td>
<td>0.000</td>
</tr>
<tr>
<td>Obsessive-compulsive disorder</td>
<td>27.5%</td>
<td>0.2%</td>
<td>0.000</td>
</tr>
<tr>
<td>Generalised anxiety</td>
<td>25.0%</td>
<td>0.6%</td>
<td>0.000</td>
</tr>
<tr>
<td>Depressive episode</td>
<td>17.5%</td>
<td>0.7%</td>
<td>0.000</td>
</tr>
<tr>
<td>Separation anxiety</td>
<td>7.5%</td>
<td>0.8%</td>
<td>0.000</td>
</tr>
<tr>
<td>Specific phobia</td>
<td>7.5%</td>
<td>1.0%</td>
<td>0.001</td>
</tr>
<tr>
<td>Social phobia</td>
<td>5.0%</td>
<td>0.3%</td>
<td>0.000</td>
</tr>
<tr>
<td>Panic attacks</td>
<td>2.5%</td>
<td>0.1%</td>
<td>0.06</td>
</tr>
<tr>
<td>Conduct disorders</td>
<td>27.5%</td>
<td>4.7%</td>
<td>0.000</td>
</tr>
<tr>
<td>Oppositional defiant disorder</td>
<td>15.0%</td>
<td>2.5%</td>
<td>0.000</td>
</tr>
<tr>
<td>Other conduct disorders</td>
<td>12.5%</td>
<td>2.2%</td>
<td>0.000</td>
</tr>
<tr>
<td>Hyperkinetic disorders</td>
<td>15.0%</td>
<td>1.3%</td>
<td>0.000</td>
</tr>
<tr>
<td>Hyperkinesis</td>
<td>12.5%</td>
<td>1.1%</td>
<td>0.000</td>
</tr>
<tr>
<td>Other hyperkinetic disorder</td>
<td>2.5%</td>
<td>0.2%</td>
<td>0.10</td>
</tr>
<tr>
<td>Less common disorders</td>
<td>10%</td>
<td>0.5%</td>
<td>0.000</td>
</tr>
</tbody>
</table>

"Continuity adjusted χ²."
Clinical difference between tic and chorea subgroups (Table 3)

Table 3 presents comparisons between the clinical features.

DISCUSSION

We report our experience of post-streptococcal dyskinetic movement disorders in a tertiary care setting. Historically, differentiation of chorea, tics, and myoclonus has sometimes been difficult in the context of “Sydenham’s chorea”, and sometimes two or more movement disorder phenotypes co-exist. Indeed, Kerbeshian et al described a recent case of post-streptococcal tics in the context of Sydenham’s chorea. It is perhaps not surprising that a variety of movement disorders may occur in the context of post-streptococcal neurological disease. Rarely do basal ganglia syndromes result in only one extrapyramidal phenotype; for example, although chorea is the classical phenotype of Huntington’s disease, motor tics and akinetic rigid phenotypes are also recognized.22-23

Recently, the spectrum of post-streptococcal movement disorders has expanded beyond chorea to include motor and vocal tics, dystonia,24-25 and myoclonus.22 In this report, chorea and tics were the most prevalent phenotypes, although this study was not epidemiological in design and therefore does not represent a community sample. It was possible to classify the majority of dyskinesias without difficulty, although occasionally mixed movement disorders were present. By analysing differences between the chorea and tic subgroup, we attempted to determine what variables may dictate phenotypic expression. Although the patient age did not clearly influence the dyskinesia phenotype, the sex distribution showed male predominance in the tic cohort and female predominance in the chorea subgroup. This sex distribution has been previously reported in Sydenham’s chorea after puberty25 and tic disorders,26 and may suggest an influence of sex hormones on phenotypic expression. The fact that oestrogen can precipitate chorea (chorea gravidarum and oral contraceptive pill) supports the possible role of oestrogen in the chorea phenotype.27 It was notable that there was a modestly increased prevalence of neuropsychiatric disorders (particularly ADHD) preceding movement disorder onset. It is possible that ADHD could represent a specific neurodevelopmental risk factor for the later development of post-streptococcal movement disorders. Alternatively, the preceding psychiatric symptoms may be a consequence of previously unrecognised episodes of post-streptococcal autoimmunity. Our longitudinal and epidemiological studies would address these alternate hypotheses. It is also possible that the movement disorder phenotype is partly related to the particular cortico-striatal tracts involved in disease pathogenesis.24

Vocal tics were common in the motor tic subgroup; however they were not exclusive to this group. Indeed, vocal tics are an unusual but previously recognised feature of Sydenham’s chorea. Other than extrapyramidal movements, additional neurological features were uncommon, although sleep disturbance (particularly insomnia) occurred in a significant proportion. It could be argued that the sleep disturbance is due to the disruption of normal sleep patterns by extra movements. Alternatively, the aberrant neurochemistry producing the movement disorder could also affect sleep pathways. Recent reports of sleep disturbance in Parkinson’s disease and Huntington’s disease support this putative hypothesis.26-27

Emotional and behavioural alteration was a common accompanying feature of the acute disease, regardless of the movement phenotype. The acute behavioural changes were often dramatic and rapid. Frequently, the children suffered a “change in personality”, and became emotionally labile or aggressive. After the acute phase, formal interview showed a high prevalence of ICD-10 psychiatric diagnoses. As shown in previous cohorts of SC and PANDAS,13-19 emotional disorders (particularly obsessive-compulsive disorder and anxiety disorders) were the most common, and the incidence of obsessive-compulsive disorder (OCD) was more common in chronic or relapsing SC.22 Indeed, OCD in this cohort was limited to the patients whose movement disorder had been present for more than one year. The shorter mean duration of illness in the SC cohort may be responsible for the reduced incidence of OCD in this subgroup. Otherwise, there were no clear differences in the psychiatric morbidity between the chorea and tic subgroups in this study. In addition to emotional disorders, conduct disorders and attention deficit disorders (such as ADHD) were also common. By contrast, psychotic symptoms were rare, although they have been occasionally described in Sydenham’s chorea.23 It is important to note that the psychiatric complications frequently remain long after the acute movement disorder has resolved.7

The main difference between the chorea and tic subgroups was the presence of systemic features (carditis and arthritis) that were exclusive to the chorea subgroup. The cause of this important difference is unknown although we acknowledge that systematic cardiac examination in PANDAS patients has not been performed in this, or other case series. Although some patients within this cohort have had transient disease or resolution of the movement disorder within a year, a large proportion of patients have had persistent or relapsing disease. The high proportion of patients with protracted disease may be due to selection bias, as patients with milder transient disease are unlikely to be referred to a tertiary referral centre. Previous studies suggest that Sydenham’s chorea becomes persistent in 20–50% of patients.23-24 Swedo’s proposed diagnostic criteria for PANDAS require two or more exacerbations of motor tics or OCD with streptococcal infections.5 All of the tic patients in this cohort fulfill a diagnosis of PANDAS. If we believe that Sydenham’s chorea and PANDAS are biologically similar disorders, Swedo’s clinical criteria would exclude a significant proportion of patients with monophasic disorders. Laboratory confirmation of recent BHS infection is necessary for a diagnosis of post-streptococcal dyskinesia; however positive BHS serology is prevalent in paediatric populations and is unlikely to be a specific diagnostic tool used in isolation. Indeed, 18% of the neurological controls had increased streptococcal serology. Previous childhood control groups in the USA have even higher rates of positive streptococcal serology.22 This has consequently lead to diagnostic difficulty, and even questioned whether the “PANDAS” phenotype exists (critically reviewed by Singer and Loiselle36). The proposed mediators of disease are antibodies reactive against brain epitopes. Anti-brain antibodies appear to be a useful marker in acute Sydenham’s chorea and post-streptococcal dystonia,24 although their usefulness in PANDAS (and Tourette syndrome) is more contentious.29 Ninety three per cent of the dyskinetic patients reported in this paper had positive anti-brain antibodies using these methods (paper attached).

The prevalence of movement and emotional disorders in first degree family relatives suggests that a genetic predisposition is important in disease development, in addition to the environmental trigger.24 It could be argued that the high incidence of neuropsychiatric disease in first degree family members is due to a genetically determined neurodevelopmental vulnerability. Alternatively, the psychiatric disease in parents and siblings could have had a psychological impact on the patients. Our more favoured hypothesis is that disease is related to a genetically determined autoimmune predisposition. The positive family history of post-streptococcal
autoimmune syndromes (Sydenham’s chorea, PANDAS, and rheumatic fever) in this study and previous cohorts of SC supports this genetic immune hypothesis. It has been recognised that patients with rheumatic fever have a high expression of a B lymphocyte surface marker, B8/17. Patients with Sydenham’s chorea and PANDAS also have significantly higher expression of this lymphocyte marker compared to healthy and autoimmune controls, although the importance of this marker is unknown. Additionally, it is also possible that genetic vulnerability is mediated via a combination of these mechanisms (neurochemical, immunological, and psychological).

This report does not address the important issue of treatment. Although penicillin prophylaxis throughout childhood has been shown to be effective at reducing relapses in rheumatic fever and SC, no similar study has been adequately performed in PANDAS. However, one group reported that prompt antibiotic treatment of pharyngeal infections lead to an improvement in PANDAS neuropsychiatric symptoms. Although immune therapies such as steroids, immunoglobulin, and plasma exchange have been successfully used in SC and PANDAS, the significant side effects of these therapies preclude routine use until further studies prove their benefit.

In conclusion, a broad spectrum of extrapyramidal movements and neuropsychiatric disorders may occur after BHS infection. Although the clinical similarities between the chorea and tic subgroups suggest that SC and PANDAS may be two phenotypes of the same immune-mediated basal ganglia disorder, other authors have highlighted the differences. Phenotypic expression may depend on other variables including the specific cortico-striatal circuits involved, developmental status, genetic predisposition, and patient’s sex. There is phenotypic similarity between post-streptococcal CNS syndromes and common neuropsychiatric disease such as tic disorders, Tourette syndrome, ADHD, and OCD. Improved understanding of the disease mechanism in post-streptococcal CNS disease could significantly improve our knowledge of the neurochemistry and neuroanatomy of common childhood diseases.

ACKNOWLEDGEMENTS

This work was undertaken by Great Ormond Street Hospital for Children NHS Trust who received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive. RCD holds a research training fellowship awarded by Action Research, and the Barnwood House Trust, UK.

Authors’ affiliations

R C Dale, I Heyman, R A H Surtees, B G R Neville, Neurosciences Unit, Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, London, UK
A J Church, G Giovannoni, Department of Neuroinflammation, Institute of Neurology, London, UK
R Goodman, Child and Adolescent Psychiatry Unit, Institute of Psychiatry, London, UK

REFERENCES

31 Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source. PD. Neurology 2002;58:341-6.

ARCHIVIST

Randomisation understood but not accepted

There is evidence that patients may neither understand nor accept randomisation in clinical trials. In a study in North Staffordshire (Cicely Kerr and colleagues. Journal of Medical Ethics 2004;30:80–4) adults attending further education classes appeared to understand randomisation but not accept it.

The 130 participants in the study were aged between 18 and 70 (mean 32 years), 67% were women, and their occupations ranged from unskilled to managerial or professional. Most were not formally educated beyond GCSE or O levels (usually taken at 16 years). They were given two hypothetical scenarios (one medical and one nonmedical) in which people needed to be allocated to two groups. Five methods of allocation were proposed: computer allocation, with no information about individuals, toss of a coin, drawing from a hat, personal preference, or allocation in turn. They were asked to decide for each of these methods whether it was random or not random. Most participants (75–90%) judged that computer allocation, tossing a coin, and drawing from a hat were random methods and asking people for their preference was not random. They were more or less equally divided about the status of allocation-in-turn. Similar answers were given whether considering the medical or the nonmedical scenario.

Participants were then asked to imagine they were to take part in a clinical trial comparing two drugs both known to be beneficial. They had to decide which of the same five methods would be acceptable for allocation to one or the other drug. Half were given a brief written justification for the use of randomisation and half were not. Among participants who correctly judged each method to be random or not random in the first part of the study most (60%) if given the written justification for randomisation, 75% if not) considered allocation by patient preference acceptable. Most (62–72% of the group not given the written justification) thought that computer allocation, tossing a coin, and drawing from a hat, or allocation-in-turn were not acceptable. The written justification did not change attitudes except towards computer randomisation which was acceptable to 38% of participants not given the justification and 58% of those given it.

Most people are able to distinguish between random and non-random methods of allocation but most would not find randomisation acceptable in a clinical trial. Computer allocation is seen as more appropriate than tossing a coin or drawing from a hat. More needs to be done to explain the reasons for randomisation in more detail and to address people’s questions.

Question—If some people choose drug A and some drug B, what’s wrong with giving them their choice and seeing how they get on? Answer—To obtain reliable results we must compare like with like. The purpose of randomisation is not just to allocate people to groups but to try to make sure that the groups are as alike as possible; one group is not older, sicker, or different from the other in any way that might affect their response to treatment. With large enough numbers of people any differences should be evened out by randomisation; chance should make it likely that more or less the same numbers of older or sicker people (or those different in ways nobody has thought of) are allocated to each group. Giving people their choice would not achieve that and the results of the trial would be unreliable; we would still not know for sure which drug was better. It would, of course, be completely unethical to allocate anybody to a treatment known beforehand to be inferior. Response—O.K. I’ll buy that.
Dyskinesias and associated psychiatric disorders following streptococcal infections

R C Dale, I Heyman, R A H Surtees, A J Church, G Giovannoni, R Goodman and B G R Neville

Arch Dis Child 2004 89: 604-610
doi: 10.1136/adc.2003.031856

Updated information and services can be found at:
http://adc.bmj.com/content/89/7/604

These include:

References
This article cites 45 articles, 10 of which you can access for free at:
http://adc.bmj.com/content/89/7/604#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Child and adolescent psychiatry (paediatrics) (683)
- Anxiety disorders (including OCD and PTSD) (28)
- Conduct disorder (11)
- Drugs: CNS (not psychiatric) (497)
- Epidemiologic studies (1818)
- Eye Diseases (174)
- Mood disorders (including depression) (39)
- Personality disorders (10)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/